Breast Cancer Clinical Trial

A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive V937 in Combination with Pembrolizumab (MK-3475). The primary objective for Part 1 is to evaluate the objective response rate, and the primary objective for Part 2 is to determine the safety and tolerability of V937 administered in combination with pembrolizumab.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Locally-advanced disease that is not amenable to surgery or radiation, or Stage IV advanced/metastatic solid tumor malignancies
Histologically- or cytologically-confirmed diagnosis of an advanced/metastatic solid tumor.
Measurable disease by RECIST 1.1 criteria as assessed by investigator. Target lesions in a previously irradiated area will be considered measurable if progression has been demonstrated in such lesions
Submitted a baseline tumor sample for analysis. Participants enrolling in Part 2 Cohorts D-F may enroll without submitting a tumor sample if all other enrollment criteria are met.
Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale obtained within 72 hours prior to the first dose of study intervention
If participant has known human immunodeficiency virus (HIV)-positive disease, participant must have well-controlled HIV on antiretroviral therapy (ART), per study criteria.
Adequate organ function
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 120 days: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR must agree to use contraception unless confirmed to be azoospermic.

Female participants are eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

Is not a woman of childbearing potential (WOCBP)
Is a WOCBP and using a contraceptive method that is highly effective, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention.
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Part 1, All Cohorts: participants must have at least one injectable lesion amenable to injection and/or biopsy.

Part 1, Cohort A:

Locally recurrent, inoperable OR metastatic breast cancer treated with at least 1 prior line of therapy in the metastatic setting with skin involvement and/or subcutaneous lesions or accessible lymph nodes amenable to local injection. An exception would be allowed for participants who are not eligible to receive chemotherapy.
Diagnosis of triple-negative breast cancer (estrogen receptor, progesterone receptor, and HER2-receptor negative status)

Part 1, Cohort B:

Histologically confirmed advanced or metastatic head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx considered incurable and/or treated with no more than 1 previous line of therapy
Tumors must be PD-L1+
Documentation of HPV status for oropharyngeal cancers. Other HNSCC subtypes may submit HPV testing, but is not required.

Part 1, Cohort C:

Histologically confirmed cutaneous squamous cell carcinoma (cSCC) as the primary site of malignancy
Recurrent/metastatic disease only: Has metastatic disease defined as disseminated disease distant from the initial/primary site of diagnosis and/or with a history of locally-recurrent disease previously treated with surgery and/or radiotherapy, which is now incurable
Locally-advanced disease only: Must be ineligible for surgical resection per study criteria, and must have received prior radiation therapy to the index site or deemed ineligible for radiation therapy

Part 2, Solid Tumors+Liver Metastases Dose Level 1-3 arms:

Histologically-confirmed advanced/metastatic solid tumor that has progressed on all treatment known to confer clinical benefit
Metastatic liver lesion(s) not exceeding one-third of the total liver volume AND a minimum of one injectable liver lesion

Part 2, Cohort D:

Advanced hepatocellular carcinoma (HCC) following progression on, or intolerance to, sorafenib or lenvatinib with no curative options
Diagnosis of HCC confirmed by radiology, histology, or cytology
Child-Pugh Class A score
If a participant has a history of hepatitis C virus (HCV) infection, then he/she must have been successfully treated for this condition
Controlled (treated) hepatitis B participants will be allowed if they meet protocol-specified criteria
Participants who are anti-hepatitis B core (HBc) positive, negative for hepatitis B surface antigen (HBsAg), negative or positive for anti-hepatitis B surface (HBs), and who have an HBV viral load under 100 IU/mL, do not require HBV anti-viral prophylaxis

Part 2, Cohort E:

Histologically- or cytologically-confirmed diagnosis of locally advanced, unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Received at least one prior line of therapy that includes a platinum/fluoropyrimidine doublet or triplet regimen
Had proven clinical progression 6 months following (or during) last dose of adjuvant or neo-adjuvant therapy
Human epidermal growth factor receptor 2 (HER2) negative status; or, those with HER2 positive status AND documented disease progression on a prior regimen containing trastuzumab

Exclusion Criteria:

Chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to first dose of study intervention, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better
If major or minor surgery was performed at/near the area being considered for injection, participant must be recovered from toxicity and/or complications of intervention
If participant has had injection or radiation therapy, participant must be recovered from toxicity and/or complications of intervention
History of second malignancy, unless potentially curative treatment has been completed with no further evidence of malignancy
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with treated brain metastases may participate if lesions are radiologically stable.
Active infection requiring therapy, except HIV criteria as stated above, and HBV and HCV criteria for HCC cohort as stated above
History of interstitial lung disease
History of noninfectious pneumonitis requiring active steroid therapy or ongoing pneumonitis
Active autoimmune disease that required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy
Known Hepatitis B or C infections or known to be positive for HBsAg/HBV deoxyribonucleic acid (DNA) or Hepatitis C Antibody or ribonucleic acid (RNA)
History of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Known hypersensitivity to V937 and/or pembrolizumab or any of their excipients
Received prior therapy with anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1) agents, Talimogene Laherparepvec (T-VEC), or any other oncolytic virus therapies
Received a live or live-attenuated vaccine within 30 days prior to first dose of study intervention. Administration of killed vaccines is allowed.
Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention

Part 2, Cohort D:

Has had esophageal or gastric variceal bleeding within the last 6 months
Has had clinically diagnosed hepatic encephalopathy in the 6 months prior to initiation of study intervention

Part 2, Cohort E:

Squamous cell or undifferentiated gastric cancer

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

185

Study ID:

NCT04521621

Recruitment Status:

Active, not recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 29 Locations for this study

See Locations Near You

John Theurer Cancer Center ( Site 0004)
Hackensack New Jersey, 07601, United States
Providence Portland Medical Center ( Site 0001)
Portland Oregon, 97213, United States
Princess Margaret Cancer Centre ( Site 0031)
Toronto Ontario, M5G 2, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0032)
Montreal Quebec, H2X 3, Canada
Hopital La Timone ( Site 0051)
Marseille Bouches-du-Rhone, 13005, France
Centre Hospitalier Lyon-Sud ( Site 0055)
Pierre Benite Rhone-Alpes, 69495, France
Gustave Roussy ( Site 0053)
Villejuif Val-de-Marne, 94800, France
Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 0172)
Heidelberg Baden-Wurttemberg, 69120, Germany
Universitaetsklinikum Tuebingen ( Site 0171)
Tuebingen Baden-Wurttemberg, 72076, Germany
Orszagos Onkologiai Intezet ( Site 0070)
Budapest , 1122, Hungary
HaEmek Medical Center ( Site 0071)
Afula , 18341, Israel
Hadassah Medical Center. Ein Kerem ( Site 0072)
Jerusalem , 91120, Israel
Sourasky Medical Center ( Site 0073)
Tel Aviv , 64239, Israel
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
Milano , 20141, Italy
National Cancer Center Hospital East ( Site 0166)
Kashiwa Chiba, 277-8, Japan
Helse Bergen HF - Haukeland Universitetssykehus ( Site 0162)
Bergen Hordaland, 5021, Norway
Oslo Universitetssykehus Radiumhospitalet ( Site 0161)
Oslo , 0379, Norway
Clinica San Gabriel ( Site 0097)
Lima , 15087, Peru
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 0181
Warszawa Mazowieckie, 02-78, Poland
Centro Hospitalar Universitário Lisboa Norte, E.P.E. - Hospital de Santa Maria ( Site 0192)
Lisbon Lisboa, 1649-, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 0191)
Porto , 4200-, Portugal
Hospital Universitari Vall d Hebron ( Site 0121)
Barcelona , 08035, Spain
Clinica Universitaria de Navarra ( Site 0122)
Madrid , 28027, Spain
Chang Gung Medical Foundation - Kaohsiung ( Site 0145)
Kaohsiung , 833, Taiwan
China Medical University Hospital ( Site 0144)
Taichung , 40447, Taiwan
National Cheng Kung University Hospital ( Site 0142)
Tainan , 704, Taiwan
National Taiwan University Hospital ( Site 0141)
Taipei , 10002, Taiwan
Mackay Memorial Hospital ( Site 0143)
Taipei , 10449, Taiwan
Chang Gung Memorial Hospital - Linkou Branch ( Site 0146)
Taoyuan , 333, Taiwan

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

185

Study ID:

NCT04521621

Recruitment Status:

Active, not recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider